Update S3-Leitlinie Zervixkarzinom: Diagnostik, Therapie und Nachsorge

Stübs F, Beckmann M, Fehm T (2022)

Publication Type: Journal article

Publication year: 2022

Journal

Abstract

There is constant progress in the treatment of women with cervical cancer. Therefore, the German S3 guideline requires regular revision. The new statements and recommendations are based on a systematic literature review. The revision process involved around 50 specialist societies under the expert guidance of the Association of the Scientific Medical Societies in Germany (Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften, AWMF). The new standard of care in surgical therapy for cervical cancer up to FIGO stage IB1 is open radical hysterectomy. The evidence base for the role of intensity-modulated radiotherapy and individualized brachytherapy was strengthened. Patients with metastatic cervical cancer benefit from addition of bevacizumab to standard chemotherapy in first-line treatment. From the second line onward, the use of pembrolizumab is recommended for women with PD-L1-positive cervical cancer.

Authors with CRIS profile

Frederik Stübs Department of Obstetrics and Gynaecology Matthias Beckmann Lehrstuhl für Geburtshilfe und Frauenheilkunde

Involved external institutions

Heinrich-Heine-Universität Düsseldorf

Germany (DE)

How to cite

APA:

Stübs, F., Beckmann, M., & Fehm, T. (2022). Update S3-Leitlinie Zervixkarzinom: Diagnostik, Therapie und Nachsorge. Best Practice Onkologie. https://doi.org/10.1007/s11654-022-00405-4

MLA:

Stübs, Frederik, Matthias Beckmann, and Tanja Fehm. "Update S3-Leitlinie Zervixkarzinom: Diagnostik, Therapie und Nachsorge." Best Practice Onkologie (2022).

BibTeX: Download